

Sirolimus Multicentre International Lymphangioleiomyomatosis Efficacy and Safety trial (the MILES trial): Canadian component

Submission date 04/02/2008	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 04/02/2008	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 29/10/2013	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Study website

<http://rarediseasesnetwork.epi.usf.edu/rldc/centers/uhn-toronto.htm>

Contact information

Type(s)

Scientific

Contact name

Dr Gregory Paul Downey

Contact details

11C-1183
Toronto General Hospital
Toronto, Ontario
Canada
M5G 1L7
+1 416 340 4996
gregory.downey@uhn.on.ca

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

NCT00414648

Secondary identifying numbers

MCT-83051

Study information

Scientific Title

Sirolimus Multicentre International Lymphangioleiomyomatosis Efficacy and Safety: Canadian component - a placebo-controlled, randomised, parallel group trial

Acronym

MILES

Study objectives

1. Implement a double-blind, placebo-controlled, 'intention to treat' based, multicentre protocol for the determination of the safety and efficacy of sirolimus in patients with lymphangioleiomyomatosis (LAM)
2. Determine the correlation between changes in lung function and questionnaire-based assessments of dyspnoea, quality of life, fatigue, and degree of health impairment in LAM trial patients who are taking sirolimus or placebo

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Research Ethics Board of University Health Network, Toronto (Canada) approved on 07/12/2007 (ref: 07-095-A)
2. Institutional Review Board of Niigata University Medical and Dental Hospital (Japan) approved on the 24/07/2007 (ref: NH19-003)
3. Institutional Review Board (Federalwide Assurance # 00002988) of Cincinnati Childrens Hospital Medical Center, Cincinnati (USA) approved on 11/01/2008 (ref: 04-11-17)

Ethics approval from Australia pending.

Study design

International, multicentre, placebo-controlled, randomised, parallel group trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Lymphangioleiomyomatosis (LAM)

Interventions

This is a multicentre, international, intention to treat, placebo-controlled, randomised parallel, drug/diagnostic, efficacy and safety trial with study participant, study investigator, caregiver, outcome assessor, and data analyst blinded.

1. Experimental group: sirolimus (rapamycin), daily dose of 2 mg during 12 months; follow up only for additional 12 months
2. Control group: matching placebo of active treatment, 1 pill daily for 12 months; follow up only for additional 12 months

Contact for public queries same as below. Please note that you can also contact Dr Lianne Singer at lianne.singer@uhn.on.ca for details on this trial (scientific and public queries).

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Sirolimus (rapamycin)

Primary outcome measure

FEV1 slope response, measured at 12 months.

Secondary outcome measures

Measured at 12 months:

1. Six minute walk testing
2. Quantitative CT of the lung
3. Quality of life questionnaires (St George Respiratory Questionnaire, 36-item short form health survey [SF-36])
4. Forced vital capacity (FVC)
5. Diffusing capacity of the lung for carbon monoxide (DLCO)

Overall study start date

01/06/2007

Completion date

31/12/2010

Eligibility

Key inclusion criteria

1. Women, aged 18 years and older
2. Signed and dated informed consent

3. Diagnosis of LAM as determined by biopsy (lung, abdominal mass, lymph node or kidney) and chest computed tomography [CT] scan findings compatible with LAM; or compatible chest CT scan findings in the setting of tuberous sclerosis, angiomyolipomata (diagnosed by CT, magnetic resonance imaging [MRI] or biopsy), or chylous pleural effusion (verified by thoracentesis)

4. Forced expiratory volume in one second (FEV1) less than or equal to 70% of predicted during baseline visit after bronchodilator

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Female

Target number of participants

260

Key exclusion criteria

1. History of myocardial infarction, angina or stroke related to atherosclerosis
2. Pregnancy or breast feeding, inadequate contraception
3. Significant haematologic or hepatic abnormality (i.e., transaminase levels greater than 3 times the upper limit of normal range, haematocrit [HCT] less than 30%, platelets less than 80,000 /cumm, adjusted absolute neutrophil count less than 1,000/cumm, total white blood cell count [WBC] less than 3,000/cumm)
4. Intercurrent infection at initiation of sirolimus
5. Recent surgery 2 months (involving entry into a body cavity or requiring sutures)
6. Use of an investigational drug within the last 30 days
7. Uncontrolled hyperlipidaemia
8. Previous lung transplantation
9. Inability to attend scheduled clinic visits
10. Inability to give informed consent
11. Inability to perform pulmonary function testing
12. Creatinine greater than 2.5 mg/dl (greater than 220 µmol/L)
13. Chylous ascites sufficient to affect diaphragmatic function on pulmonary function tests (PFTs)
14. Pleural effusion sufficient to affect pulmonary function based on the opinion of the Site Investigator (generally greater than 500 cc)
15. Acute pneumothorax within the past 2 months (as pneumothorax can alter baseline PFT results)
16. History of malignancy in the past two years, other than squamous or basal cell skin cancer
17. Use of oestrogen containing medications

Date of first enrolment

01/06/2007

Date of final enrolment

31/12/2010

Locations

Countries of recruitment

Australia

Canada

Japan

United States of America

Study participating centre

11C-1183

Toronto, Ontario

Canada

M5G 1L7

Sponsor information

Organisation

University Health Network (Toronto) (Canada)

Sponsor details

200 Elizabeth Street

Toronto, Ontario

Canada

M5G 2C4

Sponsor type

Research organisation

Website

<http://www.uhn.ca/index.htm>

ROR

<https://ror.org/042xt5161>

Funder(s)

Funder type

Research organisation

Funder Name

Canadian Institutes of Health Research (CIHR) (Canada) - <http://www.cihr-irsc.gc.ca> (ref: MCT-83051)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	28/04/2011		Yes	No
Results article	results	01/08/2013		Yes	No